Abstract
The TLX1 gene (10q24) codes for a homeodomain transcription factor not expressed in normal T lymphopoiesis. It’s expression as evaluated by RQ-PCR has been reported in 20–50% of T-ALLs while standard cytogenetic identifies TLX1 translocations to T cell receptor (TCR) genes in only 4–14% of T-ALLs. Accordingly, the stringency of the association between TLX1-TCR translocations and TLX1 overexpression has been questioned. To our knowledge, no systematic search for 10q24 translocations by FISH or molecular means has been conducted. Published T-ALL series demonstrate that a proportion of samples express TLX1 at very high levels while the remaining express TLX1 at either low or undetectable levels. In the absence of a uniform threshold, the biological significance of TLX1 levels of expression requires more exploration as it might account for the discrepancies regarding the prognosis impact of TLX1 expression and allow better T-ALL stratification. We have studied 224 unselected T-ALLs (147 adults and 77 children). Levels of TLX1 expression, assessed by RQ-PCR, were correlated to immunophenotypic, oncogenetic and molecular cytogenetic analysis. Thirty-two T-ALLs (14%, 27 adults and 5 children) expressed TLX1 at high levels (TLX1-high group) with a median level (normalised with ABL) of 746%. Fourty-nine samples (22%, 36 adults and 13 children) expressed TLX1 at lower levels (TLX1-low group) with a median level of 0,1% (range: 0,002%–11%). Caryotypes were available for 144 samples and demonstrated a 10q24 abnormality in only 11 cases, all within the TLX1-high group. Ongoing molecular analysis (FISH and LM-PCR) have revealed 17 additional 10q24 translocations/abnormalities among the TLX1-high samples with available material. Among those 17 samples, 12 had a representative caryotype without 10q24 abnormalities. In contrast, the 10q24 locus was normal in all 6 TLX1-low T-ALLs tested by FISH. Oncogenetic data show that HOX11-high T-ALLs form a homogeneous group, without coexisting TLX3, CALM-AF10 or TAL1 deregulation while TLX1-low and TLX1-negative T-ALLs often express either TLX3, CALM-AF10 or TAL1. Immunophenotypic data show that TLX1-high T-ALLs correspond to a β-selection stage of maturation arrest while TLX1-low T-ALLs show heterogeneous stages of maturation arrest: 20 immature(IM), 17 IMβ/pre-αβ, 5 TCRαβ and 6 TCRγδ. The respective prognosis of T-ALLs in correlation with their TLX1 expression level is currently being analysed. We conclude that virtually all T-ALLs expressing TLX1 at high level bear a 10q24 translocation and form a distinct homogeneous oncogenic group. Caryotype analysis largely underestimates 10q24 translocations. A uniform definition of TLX1 expression positivity has impact on T-ALL stratification in clinical protocols. Based on cytogenetic, immunophenotypic and oncogenetic arguments, we propose a definition of TLX1(+) T-ALLs restricted to T-ALLs expressing high levels (>100% ABL) of TLX1 and/or having a genetic abnormality implicating TLX1. T-ALLs expressing low levels of TLX1 do not share these characteristics and their clinical relevance should be assessed separately.
Disclosures: J.Bergeron is a Research Fellow of The Terry Fox Foundation through an award from the National Cancer Institute of Canada.; J.Bergeron is a Research Fellow of The Terry Fox Foundation through an award from the National Cancer Institute of Canada.
Author notes
Corresponding author
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal